Rational bases for using oxygen-ozonetherapy as a biological response modifier in sickle cell anemia and β-thalassemia: A therapeutic perspective

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 1, 2004, Pages 38-44

  Bocci, Velio ^a   Aldinucci, C ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Nitrogen monoxide; Oxidative stress; Oxygen ozone therapy; Ozone tolerance; Sickle cell anemia; thalassemia

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTIANEMIC AGENT; ANTIBODY; ANTIOXIDANT; ASCORBIC ACID; BIOLOGICAL RESPONSE MODIFIER; CLOTRIMAZOLE; CYANIC ACID; DEFERIPRONE; DEFEROXAMINE; FOLIC ACID; HYDROXYUREA; METHYLPREDNISOLONE; MULTIVITAMIN; OXYGEN; OZONE; PEGINTERFERON; POLAXAMER 188; POTASSIUM CHANNEL BLOCKING AGENT; RIBAVIRIN; SELENIUM; THIOCTIC ACID; UNCLASSIFIED DRUG; UREA; VASODILATOR AGENT;

AERATION; ANTIOXIDANT ACTIVITY; ARTICLE; BETA THALASSEMIA; BLOOD AUTOTRANSFUSION; CHRONIC DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; LONG TERM CARE; MUTAGENICITY; NONHUMAN; OXIDATIVE STRESS; QUALITY OF LIFE; SICKLE CELL ANEMIA; TREATMENT OUTCOME;

EID: 4444365405     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in beta-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants. Blood 1996; 88: 3608-14.
2. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of β-thalassemia intermedia erythrocytes. Br J Haematol 2000; 111: 1-4.
3. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest 2002; 32 (Suppl. 1): S55-60.
4. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82: 521-33.
5. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm. Proc Natl Acad Sci USA 2002; 99: 3047-51.
6. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. Sickle cell disease: The neurological complications. Ann Neurol 2002; 51: 543-52.
7. Hoppe CC, Walters MC. Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol 2001; 11 85-90.
8. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-71.
9. Cooperative Urea Trials Group. Treatment of sickle cell crisis with urea in invert sugar: A controlled trial. JAMA 1974; 228: 1125-8.
10. Charache S, Duffy TP, Jander N, Scott JC, Bedine M, Morrell R. Toxic-therapeutic ratio of sodium cyanate. Arch Intern Med 1975; 135: 1043-7.
11. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330: 733-7.
12. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 2001; 286: 2099-106.
13. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxynrea in Sickle Cell Anemia. Am J Hematol 2000; 64: 26-31.
14. de Montalembert M, Begue P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child 1999; 81: 437-9.
15. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340: 1021-30.
16. Venigalla P, Motwani B, Allen S, Agarwal M, Alva M, Westerman M, Feldman L. A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 2002; 100: 363.
17. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97: 1227-34.
18. Kaul DK, Tsai HM, Liu XD. Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000; 95: 368-74.
19. Scott MD, van den Berg JJ, Repka T, et al. Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest 1993; 91: 1706-12.
20. Olivieri NF, Brittenham GM Non-chelating therapy and the treatment of thalassemia. blood 1997; 89: 739-61.
21. Angelucci E, Brittenham GM. McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-31.
22. Angelucci E, Muretto P, Lucarelli G. et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90: 994-8.
23. Anderson LI, Wonke B, Prescott E, Holden S, Walker IM, Pennell DI. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002; 360: 516-20.
24. Comporti M, Signorini C, Buonocore G, Ciccoli L. Iron release, oxidative stress and erythrocyte ageing. Free Radic Biol Med 2002; 32: 568-76.
25. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002; 32: 833-40.
26. Kihm AJ, Kong Y, Hong W, et al. An abundant erythroid protein that stabilizes free alpha-haemoglobin. Nature 2002; 417: 758-63.
27. Gomez M, Espinosa E. Caplan IA. Application of medicinal ozone/oxygen in patients with sickle cell anemia. Townsend Letter for Doctors 1995; 48-52.
28. Bocci V. Biological and clinical effects of ozone. Has ozonetherapy a future in medicine? Br J Biomed Sci 1999; 56: 270-9.
29. Bocci V. Oxygen-ozone therapy. A critical evaluation. Dordrecht: Kluwer Academic Publishers, 2002.
30. Vanderlinde ES, Heal JM, Blumberg N. Autologous transfusion. Br Med J 2002; 324: 772-5.
31. Morita T, Kourembanas S. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest 1995; 96: 2676-82.
32. Duckers HJ, Boehm M. True AL, et al. Heme oxygenase-1 protect against vascular constriction and proliferation. Nat Med 2001; 7: 693-8.
33. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators Inflamm 2000; 9: 271-6.
34. 2. Proc Natl Acad Sci USA 2001; 98: 355-60.
35. Jha L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996; 380: 221-6.
36. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N, Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001; 42: 1257-65.
37. Rafikova O, Rafikov R, Nudler E. Catalysis of Snitrosothiols formation by serum albumin: The mechanism and implication in vascular control. Proc Natl Acad Sci USA 2002; 99: 5913-8.
38. Rassaf T, Preik M, Kleinbongard P, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest 2002; 109: 1241-8.
39. Han TH, Hyduke DR, Vaughn MW, Fukuto JM, Liao JC. Nitric oxide reaction with red blood cells and hemoglobin under heterogeneous conditions. Proc Natl Acad Sci USA 2002; 99: 7763-8.
40. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997; 100: 1193-8.
41. Gladwin MT Schechter AN, Shelhamer JH, et al. Inhaled nitric oxice augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999; 104: 937-45.
42. Hrinczenko BW, Alayash AI, Wink DA, Gladwin MT, Rodgers GP, Schechter AN. Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport. Br J Haematol 2000; 110: 412-9.
43. Enwonwu CO. Increased metabolic demand for arginine in sickle cell anaemia. Med Sci Res 1989; 17: 997-8.
44. Rees DC, Cervi P, Grimwade D, et al. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 1995; 91: 834-7.
45. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: A novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000; 111: 498-500.
46. Jhang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxynrea. Mol Pharmacol 1997; 52: 1081-6.
47. Glover RE, Jvy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999; 55: 1006-10.
48. Wink DA, Grisham MB, Mitchell JB, Ford PC. Direct and indirect effects of nitric oxide in chemical reactions relevant to biology. Methods Enzymol 1996; 268: 12-31.
49. Parks DA, Granger DN. Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol 1983; 245: G285-9.
50. Sarnesto A, Linder N, Raivio, KO. Organ distribution and molecular forms of human xanthine dehydrogenaselxanthine oxidase protein. Lab Invest 1996; 74: 48-56.
51. Tan S, Yokoyama Y, Dickens E, Cash TG, Freeman BA, Pats DA. Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med 1993; 15: 407-14.
52. Houston M, Estevez A, Chumley R, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 1999; 274: 4985-94.
53. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001; 98: 15215-20.
54. Kuross SA, Hebbel RP. Nonheme iron in sickle erythrocyte membranes: Association with phospholipids and potential role in lipid peroxidation. Blood 1988; 72: 1278-85.
55. Amato G. Uso dell'ozonoterapia mediante grande autoemotrasfusione nella terapia delltangina abdominis. Proceedings: I Congresso IMOS, Italia, Siena, 2-4 novembre 2000.2000: 10.
56. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in health volunteers: Evidence for a recommended dietary allowance. Proc Nat Acad Sci USA 1996; 93: 3704-9.
57. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 1991; 46: 39-42.
58. Hack V, Breitkreutz R, Kinscherf R, Rohrer H, Bartsch P, Taut F, Benner A, Droge W. The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood 1998; 92: 59-67.
59. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: A systematic review. J Intern Med 2002; 251:372-92.
60. Jacobs M-T. Untersuchung uber Zwischenfalle und typische Komplikationen in der Ozon-Sauerstoff-Therapie. OzoNachrichten 1982; 1: 5.
61. Bocci V. Determinants of erythrocyte ageing: A reappraisal. Br J Haematol 1981; 48: 515-22.
62. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002; 117: 755-8.
63. Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen-ozone in rabbits. Int J Med Biol Environ 2000; 28: 109-13.